Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

NCT05830097 is registered in ClinicalTrials.gov with Coherent Biopharma (Hefei) Co., Ltd. as lead sponsor.

NCT NCT05830097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05830097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Lead sponsor
Coherent Biopharma (Hefei) Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 14, 2023
Completion date
September 30, 2025
Enrollment
260 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer colorectal, cancer of esophagus, cancer of pancreas, cancer, breast, cancer, lung